XORTX Therapeutics (XRTX) Total Liabilities (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Total Liabilities came in at $860988.0 in Q1 2026, up 13.68% YoY from $757350.0 in Q1 2025, and up 43.72% on a QoQ basis from $599071.0 in Q4 2025.
XORTX Therapeutics (XRTX) Total Liabilities (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Total Liabilities data on file, last reported at $860988.0 in Q1 2026.
- Quarterly Total Liabilities rose 13.68% year-over-year to $860988.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $860988.0 (up 13.68% YoY) and the FY2025 annual result came in at $599071.0, down 20.97% from the prior year.
- Total Liabilities improved to $860988.0 in Q1 2026, from $599071.0 in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $5.4 million in Q4 2022 to a low of $403262.0 in Q2 2023.
- A 5-year average of $1.8 million and a median of $849198.0 in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities plunged 86.47% — and 2024, when it soared 493.46%.
- Tracing XRTX's Total Liabilities over 5 years: stood at $5.4 million in 2022, then plunged by 89.68% to $553757.0 in 2023, then jumped by 36.88% to $757990.0 in 2024, then fell by 20.97% to $599071.0 in 2025, then jumped by 43.72% to $860988.0 in 2026.
- The last three Total Liabilities figures came in at $860988.0 (Q1 2026), $599071.0 (Q4 2025), and $837408.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 860,988.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 860,988.00 |
| Dec 31, 2025 | 599,071.00 |
| Sep 30, 2025 | 837,408.00 |
| Jun 30, 2025 | 711,455.00 |
| Mar 31, 2025 | 757,350.00 |
| Dec 31, 2024 | 757,990.00 |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Sep 30, 2023 | 553,757.00 |
| Jun 30, 2023 | 403,262.00 |
| Mar 31, 2023 | 599,788.00 |
| Dec 31, 2022 | 5.37 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 2.98 Mn |
| Mar 31, 2022 | 3.98 Mn |
| Dec 31, 2021 | 4.20 Mn |
| Sep 30, 2021 | 9.59 Mn |
| Dec 31, 2020 | 793,297.91 |